These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21784384)

  • 1. Cardiovascular medications and risk of cancer.
    Ocampo NV; Tafreshi J; Hauschild CL; Pai RG
    Am J Cardiol; 2011 Oct; 108(7):1045-51. PubMed ID: 21784384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of heart failure management in the elderly population.
    Cheng JW; Nayar M
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):233-49. PubMed ID: 19948300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline laboratory monitoring of cardiovascular medications in elderly health maintenance organization enrollees.
    Simon SR; Andrade SE; Ellis JL; Nelson WW; Gurwitz JH; Lafata JE; Davis RL; Feldstein A; Raebel MA
    J Am Geriatr Soc; 2005 Dec; 53(12):2165-9. PubMed ID: 16398903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses' health study.
    Michels KB; Rosner BA; Walker AM; Stampfer MJ; Manson JE; Colditz GA; Hennekens CH; Willett WC
    Cancer; 1998 Nov; 83(9):2003-7. PubMed ID: 9806660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular therapies and risk for development of diabetes.
    Pepine CJ; Cooper-Dehoff RM
    J Am Coll Cardiol; 2004 Aug; 44(3):509-12. PubMed ID: 15358012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk.
    Rafter N; Connor J; Hall J; Jackson R; Martin I; Parag V; Vander Hoorn S; Rodgers A
    N Z Med J; 2005 Oct; 118(1223):U1676. PubMed ID: 16224500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular treatment gaps: closing, but slowly.
    Selak V; Rafter N; Parag V; Tomlin A; Vander Hoorn S; Dovey S; Rodgers A
    N Z Med J; 2009 Apr; 122(1293):3564. PubMed ID: 19448790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular drug use and the incidence of erectile dysfunction.
    Shiri R; Koskimäki J; Häkkinen J; Auvinen A; Tammela TL; Hakama M
    Int J Impot Res; 2007; 19(2):208-12. PubMed ID: 16900205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of angiotensin receptor blockers and the risk of cancer.
    Pasternak B; Svanström H; Callréus T; Melbye M; Hviid A
    Circulation; 2011 Apr; 123(16):1729-36. PubMed ID: 21482967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
    Tonelli M; Bohm C; Pandeya S; Gill J; Levin A; Kiberd BA
    Am J Kidney Dis; 2001 Mar; 37(3):484-9. PubMed ID: 11228171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common cardiovascular medications in cancer therapeutics.
    Vaklavas C; Chatzizisis YS; Tsimberidou AM
    Pharmacol Ther; 2011 May; 130(2):177-90. PubMed ID: 21277894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive medications and risk of diabetes mellitus.
    Barzilay JI; Cutler JA; Davis BR
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):256-60. PubMed ID: 17420670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer in cardiovascular drug trials and vice versa: a personal perspective.
    Pfeffer MA
    Eur Heart J; 2013 Apr; 34(15):1089-94. PubMed ID: 22408033
    [No Abstract]   [Full Text] [Related]  

  • 20. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years.
    Li CI; Malone KE; Weiss NS; Boudreau DM; Cushing-Haugen KL; Daling JR
    Cancer; 2003 Oct; 98(7):1504-13. PubMed ID: 14508839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.